Will HeartSciences stock go up?

According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (39.43%) is -11.39% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for HeartSciences stock?

The HeartSciences target price is $2.81 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold HeartSciences stock right now?

HeartSciences has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (39.43%) is -11.39% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether HeartSciences stock is a good buy .

Is HeartSciences undervalued right now?

Based on analysts, the average price target downside for HeartSciences is 0.00% (1Y). According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of HeartSciences stock over the past 12 months?

The HeartSciences stock price range over the past 12 months has been $1.67 - $5.73.

What is going on with HeartSciences stock in the last 3 months?

The HeartSciences stock performance in the last quarter has been +19.06%.

Does HeartSciences offer dividend payments?

No, HeartSciences does not currently pay dividends.

What is the current market capitalization of HeartSciences?

HeartSciences's market cap is $9.18M, as of 2026-07-03 08:00.

HeartSciences Inc (HSCS) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

HSCS AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, HeartSciences Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 39% probability of outperforming the market in the next 3 months, which is 12% lower than the average probability of any stock (51%). The top positive contributor is the Earnings Countdown signal, which adds +0.55% to the probability, indicating that earnings were recently reported. The Alpha 1Y signal also adds +0.54%, despite being in the bottom 30% for risk-adjusted return. On the negative side, the Fundamentals Impact (Long Tail) detracts -2.04%, the Chart Pattern (504d) detracts -1.90%, and the Industry (GICS) classification as Health Care Equipment & Supplies detracts -1.23%. The Fear & Greed Index at 31 (extreme fear) detracts -1.05%, while the Sloan Ratio in the top 10% (high accruals) detracts -0.99%, and Maximum Volatility in the top 10% detracts -0.89%. Notable data points include Institutional Ownership at just 6.77% (bottom 20%), indicating low confidence from large investors, and Beginning Cash of only $1.10 million (bottom 10%), suggesting limited liquidity. The Net PP&E is also in the bottom 10% at $0.05 million, reflecting minimal fixed assets. On the positive side, the Earnings Countdown value of -106 days (bottom 10%) means earnings were recently released, which can reduce uncertainty. The ATR (180d) and ATR (14d) are in the bottom half, indicating relatively low volatility. Overall, the stock faces strong headwinds from weak fundamentals, high volatility, and poor earnings quality, resulting in a Strong Sell rating with a low probability of outperforming the market.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Growth+0.28%
Expected pace of revenue and earnings expansion
Volatility+0.10%
How much the stock price tends to fluctuate

Momentum-3.28%
Direction and strength of recent price movements
Valuation-3.17%
How the stock is priced relative to its fundamentals
Sentiment-2.89%
How analysts and the market view the stock
Earnings Quality-0.99%
Stability and reliability of reported earnings
Profitability-0.76%
Profitability and operating efficiency metrics
Size & Liquidity-0.68%
Company size and trading liquidity

HSCS probability advantage of beating the market (3M):

-11.39%

Technical

HeartSciences (HSCS) has a Technical Score of 3/10 because, according to only technical analysis, it has a probability advantage of -6.85% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of HSCS (43.88%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
HSCS probability advantage of beating the market (only technical, 3M)-6.85%
HSCS probability of beating the market (3M)43.88%

HSCS probability advantage of beating the market (only technical, 3M): -6.85%

The AI-powered technical analysis of HeartSciences (HSCS) is only based on the 30 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of HSCS:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	-1.37%
Technical	Upgrade to Pro to unlock	-1.33%
Technical	Upgrade to Pro to unlock	-1.22%
Technical	Upgrade to Pro to unlock	+1.06%
Technical	Upgrade to Pro to unlock	-1.04%
Technical	Upgrade to Pro to unlock	-0.89%
Technical	Upgrade to Pro to unlock	+0.78%
Technical	Upgrade to Pro to unlock	-0.73%
Technical	Upgrade to Pro to unlock	-0.54%
Technical	Upgrade to Pro to unlock	-0.45%
Technical	Upgrade to Pro to unlock	-0.44%
Technical	Upgrade to Pro to unlock	+0.44%
Technical	Upgrade to Pro to unlock	-0.44%
Technical	Upgrade to Pro to unlock	-0.39%
Technical	Upgrade to Pro to unlock	-0.32%

Rest of Alpha Signals: +0.02%

HSCS probability advantage of beating the market (only technical, 3M)Total:-6.85%
HSCS Technical Score

Significant changes Vs previous day

HSCS Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.81
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

HSCS Proven Sell Signal & Price Forecast

This is the price chart for HSCS from January 2, 2026 until today. The chart indicates, in red, the 85 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

HSCS Average Past Performance & Loss Rate

Three months after its 890 Sell signals since July 2026, HSCS had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

890 Past HSCS Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-60.79%
Average Alpha				-80.07%
Loss Rate (% Negative Perf.)				92.04%
% Negative Alpha				98.13%

HSCS Frequently Asked Questions

Will HeartSciences stock go up?
According to Danelfin AI, HeartSciences has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (39.43%) is -11.39% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for HeartSciences stock?
Is it a good time to buy, sell, or hold HeartSciences stock right now?
Is HeartSciences undervalued right now?
What was the price range of HeartSciences stock over the past 12 months?
What is going on with HeartSciences stock in the last 3 months?
Does HeartSciences offer dividend payments?
What is the current market capitalization of HeartSciences?

HeartSciences Inc Company Profile

With a focus on medical technology, Heart Test Laboratories, Inc., plays an integral role in the field of cardiovascular diagnostics. It has shaped its reputation around the production of distinguished offerings like the MyoVista wavECG - an advanced device that puts to use resting 12-lead electrocardiograph (ECG) technology. This innovative tool not only provides traditional ECG data but also offers crucial diagnostic insight into cardiac dysfunction.

Operating as a key resource for healthcare professionals, Heart Test Laboratories caters to a variety of environments where wellness takes priority. Its client roster expands from multiple clinics and doctor’s offices to urgent care centers and hospitals; they all trustfully employ the company's state-of-the-art solutions for reliable patient examinations.

Incorporated in the year 2007, Heart Test Laboratories continues its operations from Southlake, Texas - serving as its established headquarters. As it engages in enriching lives with safer and accurate diagnoses, it balances sophistication with ease-of-use in its technological exploits while catering to the ever-evolving medical landscape.

Sector:
Country:United States
Industry:
Address:550 Reserve St, Suite 360, Southlake
Employees:15
Website:heartsciences.com

Pros

Proprietary AI-driven ECG diagnostic technology

High switching costs for integrated diagnostic systems

Scalability of software-based medical diagnostics

Regulatory barriers to entry for novel devices

Potential for improved diagnostic accuracy in cardiology

Cons

Extensive regulatory approval processes for medical devices

Challenges in securing reimbursement for novel diagnostics

High capital expenditure for research and clinical trials

Physician adoption inertia for new diagnostic paradigms

Competition from established cardiac diagnostic providers

Company	AI Score	Compare
BEATHeartbeam Inc
HTFLHeartflow Inc
EWEdwards Lifesciences Corp
IRTCiRhythm Technologies, Inc.
VSEEVsee Health Inc

Company	AI Score	Compare
BEATHeartbeam Inc
HTFLHeartflow Inc
EWEdwards Lifesciences Corp
IRTCiRhythm Technologies, Inc.
VSEEVsee Health Inc

HSCS Stock AI Analysis